MedTrace Logo

Bacteriophage Clinical Trial for Periprosthetic Joint Infection of Multidrug Resistant Pseudomonas Aeruginosa

NCT06798168 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-01-29

No results posted yet for this study

Summary

This is a single patient study (SPS) that aims to test the bacteriophage treatment as an experimental treatment on a patient suffering from chronic periprosthetic joint infection (PJI) of the right hip. This patients has been suffering from an infection in the right sided hip arthroplasty with a multidrug resistant (MDR) strain of Pseudomonas aeruginosa bacteria. All treatment options for this type of infection have been exhausted. If this patient remains without treatment then there is a high risk of mortality secondary to sepsis and the only remaining surgical option for this patient is a hind quarter amputation which will be a devastating surgery that will largely affect this patients quality of life. However, a large number of published case series have shown the positive impact of combining bacteriophage therapy with antibiotics to achieve a synergistic antibacterial effect and overcome possible resistance development to clear the infection. Therefore we intend to try the bacteriophage therapy on this patients infected hip in the aim to control the infection and improve the patients quality of life.

Conditions

  • Joint Infection

Interventions

BIOLOGICAL

Combining bacteriophage therapy with antibiotics for a case with hip PJI

The treatment plan is to treat the patient with weekly intra-articular injections of a personalized phage therapy cocktail (QDP-PSA-011) for 3 consecutive weeks. This will be associated with antibiotics for 6 weeks.

Sponsors & Collaborators

  • Ottawa Hospital Research Institute

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06798168 on ClinicalTrials.gov